Skip to content
value.today
Zafgen, Inc. logo

Zafgen, Inc.

Total raised
$36 M
3 rounds on record
Latest round
$22 M
Nov 2012
First round on record
Feb 2010
Today
Went public
See the company page

Zafgen, Inc. is listed today as Larimar Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Zafgen, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2020$80 MPrivate placement after listing$50 to $250 million

Zafgen, Inc.: Private sale, May 2020

Investors in this round

24 investors had bought by the notice of Jun 10, 2020: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Zafgen, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$80 M of $80 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,800,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carole Ben Maimon, MD · Executive Officer, Director · President and CEO
  • Michael Celano · Executive Officer · Chief Financial Officer
  • Frank E. Thomas · Director
  • Jonathan Leff · Director
  • Joseph Truitt · Director
  • Peter Barrett · Director
  • Thomas Hamilton · Director
  • Thomas O. Daniel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • MTS Partners · New York, New YorkSold in CA, CO, CT, NY

Remarks in the notice

  • On a merger: “Private placement financing with institutional investors.”

Signed by Michael Celano, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 10, 2020. Read the notice at the SEC.

equitySEC
May 2020$82 MPrivate placement after listing$50 to $250 million

Zafgen, Inc.: Private sale, May 2020

Investors in this round

1 investor had bought by the notice of Jun 10, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Zafgen, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$82 M of $82 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carole Ben Maimon, MD · Executive Officer, Director · President and CEO
  • Michael Celano · Executive Officer · Chief Financial Officer
  • Frank E. Thomas · Director
  • Jonathan Leff · Director
  • Joseph Truitt · Director
  • Peter Barrett · Director
  • Thomas Hamilton · Director
  • Thomas O. Daniel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Issuance of shares pursuant to Agreement and Plan of Merger, dated December 17, 2019, as amended, by and among Larimar Therapeutics, Inc. (f/k/a Zafgen, Inc.), Zordich Merger Sub, and Chondrial Therapeutics, Inc.”

Signed by Michael Celano, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 10, 2020. Read the notice at the SEC.

equitySEC
Nov 2012$22 MNo. 3$10 to $50 million

Zafgen, Inc.: Raise no. 3, Nov 2012

Investors in this round

4 investors had bought by the notice of Dec 5, 2012: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Zafgen, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis D. Kim · Executive Officer
  • Matthias Jaffe · Executive Officer
  • Mitchell S. Bloom · Executive Officer
  • Thomas Hughes · Executive Officer, Director
  • Avi S. Goldberg · Director
  • Bruce S. Booth · Director
  • Frances S. Heller · Director
  • Kevin S. Starr · Director
  • Lou S. Tartaglia · Director
  • Peter S. Barrett · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthias Jaffe, Cfo. Source: SEC Form D, newest notice filed Dec 5, 2012. Read the notice at the SEC.

equitySEC
Jun 2011$6 MNo. 2$2 to $10 million

Zafgen, Inc.: Raise no. 2, Jun 2011

Investors in this round

6 investors had bought by the notice of Jul 12, 2011: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Zafgen, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthias Jaffe · Executive Officer
  • Mitchell S. Bloom · Executive Officer
  • Thomas Hughes · Executive Officer, Director
  • Avi S. Goldberg · Director
  • Bruce S. Booth · Director
  • Kevin S. Starr · Director
  • Louis S. Tartaglia · Director
  • Peter S. Barrett · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthias Jaffe, CFO, Treasurer & VP of Business Development. Source: SEC Form D, newest notice filed Jul 12, 2011. Read the notice at the SEC.

equitySEC
Feb 2010$8 MNo. 1$2 to $10 million

Zafgen, Inc.: Raise no. 1, Feb 2010

Investors in this round

3 investors had bought by the notice of Mar 2, 2010: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Zafgen, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $10 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthias Jaffe · Executive Officer · CFO, Treasurer & VP of Business Development
  • Mitchell S. Bloom · Executive Officer · Secretary
  • Thomas Hughes · Executive Officer, Director · CEO & President
  • Avi S. Goldberg · Director
  • Bruce S. Booth · Director
  • Dr. Liam S. Ratcliffe · Director
  • Kevin S. Starr · Director
  • Louis S. Tartaglia · Director
  • Peter S. Barrett · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthias Jaffe, CFO, Treasurer & VP of Business Development. Source: SEC Form D and 1 amendment, newest notice filed Mar 2, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Zafgen, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).

    SEC Form D · Jun 2020

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jun 2020

That is all the official record says: Zafgen, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Zafgen, Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Zafgen, Inc.
InvestorKindAmountRoundRoleSource
Atlas Venture Associates VII, Inc.Venture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Atlas Venture Associates VII, L.P.Venture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Atlas Venture Fund VII L.P.Venture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Third Rock Ventures GP, L.P.Venture capitalnot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Third Rock Ventures LPVenture capitalnot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
TRV GP, LLCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 6 investors.

Largest shareholders today

Institutions holding Larimar Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Zafgen, Inc.
NameRoleNamed in
Carole Ben Maimon, MDPresident and CEOJun 2020
Michael CelanoChief Financial OfficerJun 2020
Dennis D. KimExecutive officerDec 2012
Matthias JaffeExecutive officerDec 2012
Mitchell S. BloomExecutive officerDec 2012
Thomas HughesExecutive officerDec 2012
Carole Ben Maimon, MDPresident and CEOJun 2020
Frank E. ThomasDirectorJun 2020
Jonathan LeffDirectorJun 2020
Joseph TruittDirectorJun 2020
Peter BarrettDirectorJun 2020
Thomas HamiltonDirectorJun 2020
Thomas O. DanielDirectorJun 2020
Avi S. GoldbergDirectorDec 2012
Bruce S. BoothDirectorDec 2012
Frances S. HellerDirectorDec 2012
Kevin S. StarrDirectorDec 2012
Lou S. TartagliaDirectorDec 2012
Peter S. BarrettDirectorDec 2012
Thomas HughesDirectorDec 2012
Louis S. TartagliaDirectorJul 2011
Dr. Liam S. RatcliffeDirectorMar 2010
Ari S. GoldbergDirectorMar 2010

About

Company in Boston, United States.

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.